Why Great Science Stalls at Commercialization

Most companies do not stall because of weak science. They stall in the gap between validation and revenue. Here is what closes it.

In Life Sciences, the hard part is rarely getting to good data. It is everything that comes after. I have watched companies with beautiful science stall out, and I have watched plainer technologies win, and the difference almost never came down to the science. It came down to the decisions made around it.

I spent twenty-five years running these businesses, in Genomics, Diagnostics, and Life Science Tools, launching products and answering for the number every quarter. The same few mistakes keep showing up. Here are the three I see most, and what the companies that get past them do differently.

1. Mistaking interest for demand

Early adopters are generous. They will take the meeting, run the pilot, and tell you it is exciting. That is not a market yet. The next wave of buyers is more skeptical and slower to move. They want proof, references, and a reason the switch is worth the disruption to how they already work. Plenty of companies read that early enthusiasm as a green light to scale, then hit a wall when the mainstream customer needs a completely different case to say yes.

2. Pitching the technology, missing the decision

Founders who come from the bench tend to build the story around what the technology can do. But the people writing the check, especially scientists and clinicians, are weighing other things. Will this hold up if I stake my name on it? What happens to my credibility if it fails? Who else like me has already made this call? When the pitch is all capability, it sails past the question the buyer is actually asking. The teams that break through figure out how the decision really gets made, then put the evidence in front of it.

3. Building the commercial engine too late

Science-led companies tend to treat commercial leadership as a later problem, something to bring in once the product is ready. By then the price is anchored too low, habits have set, and whoever you hire is building the plane while flying it. Commercial capability takes time to grow. The teams that scale start working on go-to-market, pricing, and their first commercial hires while the product is still coming together, so it is in place when they need it.

What the ones who make it do differently

• Pick a narrow beachhead. Win the one segment where your evidence is strongest and the pain is sharpest before you try to be everywhere.
• Build the evidence your buyer trusts, in the form they trust it. The data that thrills your scientists is not always the data that closes the deal.
• Sequence the geographies. The same product meets very different pricing, regulation, and reimbursement depending on where you sell it, so decide what to win now and what to hold.
• Bring in commercial leadership before the launch depends on it.

The operator's view

None of this means caring less about the science. The science is what makes everything else possible. But strong science gets you taken seriously; what you do commercially decides whether you win. If you are building one of these companies, give as much thought to how it sells as to what it does. That is the half most teams underestimate, and it is the half I spend my days on.